EEG-based Signatures of Schizophrenia, Depression, and Aberrant Aging: A Supervised Machine Learning Investigation.

affective disorders early intervention electrophysiology precision psychiatry psychosis spectrum disorders support vector machine

Journal

Schizophrenia bulletin
ISSN: 1745-1701
Titre abrégé: Schizophr Bull
Pays: United States
ID NLM: 0236760

Informations de publication

Date de publication:
09 Sep 2024
Historique:
medline: 9 9 2024
pubmed: 9 9 2024
entrez: 9 9 2024
Statut: aheadofprint

Résumé

Electroencephalography (EEG) is a noninvasive, cost-effective, and robust tool, which directly measures in vivo neuronal mass activity with high temporal resolution. Combined with state-of-the-art machine learning (ML) techniques, EEG recordings could potentially yield in silico biomarkers of severe mental disorders. Pathological and physiological aging processes influence the electrophysiological signatures of schizophrenia (SCZ) and major depressive disorder (MDD). From a single-center cohort (N = 735, 51.6% male) comprising healthy control individuals (HC, N = 245) and inpatients suffering from SCZ (N = 250) or MDD (N = 240), we acquired resting-state 19 channel-EEG recordings. Using repeated nested cross-validation, support vector machine models were trained to (1) classify patients with SCZ or MDD and HC individuals and (2) predict age in HC individuals. The age model was applied to patient groups to calculate Electrophysiological Age Gap Estimation (EphysAGE) as the difference between predicted and chronological age. The links between EphysAGE, diagnosis, and medication were then further explored. The classification models robustly discriminated SCZ from HC (balanced accuracy, BAC = 72.7%, P < .001), MDD from HC (BAC = 67.0%, P < .001), and SCZ from MDD individuals (BAC = 63.2%, P < .001). Notably, central alpha (8-11 Hz) power decrease was the most consistently predictive feature for SCZ and MDD. Higher EphysAGE was associated with an increased likelihood of being misclassified as SCZ in HC and MDD (ρHC = 0.23, P < .001; ρMDD = 0.17, P = .01). ML models can extract electrophysiological signatures of MDD and SCZ for potential clinical use. However, the impact of aging processes on diagnostic separability calls for timely application of such models, possibly in early recognition settings.

Sections du résumé

BACKGROUND BACKGROUND
Electroencephalography (EEG) is a noninvasive, cost-effective, and robust tool, which directly measures in vivo neuronal mass activity with high temporal resolution. Combined with state-of-the-art machine learning (ML) techniques, EEG recordings could potentially yield in silico biomarkers of severe mental disorders.
HYPOTHESIS OBJECTIVE
Pathological and physiological aging processes influence the electrophysiological signatures of schizophrenia (SCZ) and major depressive disorder (MDD).
STUDY DESIGN METHODS
From a single-center cohort (N = 735, 51.6% male) comprising healthy control individuals (HC, N = 245) and inpatients suffering from SCZ (N = 250) or MDD (N = 240), we acquired resting-state 19 channel-EEG recordings. Using repeated nested cross-validation, support vector machine models were trained to (1) classify patients with SCZ or MDD and HC individuals and (2) predict age in HC individuals. The age model was applied to patient groups to calculate Electrophysiological Age Gap Estimation (EphysAGE) as the difference between predicted and chronological age. The links between EphysAGE, diagnosis, and medication were then further explored.
STUDY RESULTS RESULTS
The classification models robustly discriminated SCZ from HC (balanced accuracy, BAC = 72.7%, P < .001), MDD from HC (BAC = 67.0%, P < .001), and SCZ from MDD individuals (BAC = 63.2%, P < .001). Notably, central alpha (8-11 Hz) power decrease was the most consistently predictive feature for SCZ and MDD. Higher EphysAGE was associated with an increased likelihood of being misclassified as SCZ in HC and MDD (ρHC = 0.23, P < .001; ρMDD = 0.17, P = .01).
CONCLUSIONS CONCLUSIONS
ML models can extract electrophysiological signatures of MDD and SCZ for potential clinical use. However, the impact of aging processes on diagnostic separability calls for timely application of such models, possibly in early recognition settings.

Identifiants

pubmed: 39248267
pii: 7753495
doi: 10.1093/schbul/sbae150
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Else-Kröner-Fresenius-Stiftung
Organisme : EKFS-Translational Psychiatry
Organisme : NIH HHS
ID : U01MH124639-01
Pays : United States
Organisme : German Innovation Fund
Organisme : German Federal Ministry of Education and Research
Organisme : German Federal Ministry of Education and Research
ID : 01ZX1904E
Organisme : German Science Foundation
Organisme : German Ministry of Science
Organisme : German Ministry of Health

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center.

Auteurs

Elif Sarisik (E)

Max Planck Fellow Group Precision Psychiatry, Max Planck Institute of Psychiatry, Munich, Germany.
Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, Munich, Germany.
International Max Planck Research School for Translational Psychiatry (IMPRS-TP), Munich, Germany.

David Popovic (D)

Max Planck Fellow Group Precision Psychiatry, Max Planck Institute of Psychiatry, Munich, Germany.
Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, Munich, Germany.
International Max Planck Research School for Translational Psychiatry (IMPRS-TP), Munich, Germany.
German Center for Mental Health (DZPG), Partner Site Munich, Munich, Germany.

Daniel Keeser (D)

Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, Munich, Germany.
German Center for Mental Health (DZPG), Partner Site Munich, Munich, Germany.
NeuroImaging Core Unit Munich (NICUM), LMU University Hospital, LMU Munich, Munich, Germany.
Munich Center for Neurosciences, LMU Munich, Munich, Germany.

Adyasha Khuntia (A)

Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, Munich, Germany.
International Max Planck Research School for Translational Psychiatry (IMPRS-TP), Munich, Germany.

Kolja Schiltz (K)

Max Planck Fellow Group Precision Psychiatry, Max Planck Institute of Psychiatry, Munich, Germany.

Peter Falkai (P)

Max Planck Fellow Group Precision Psychiatry, Max Planck Institute of Psychiatry, Munich, Germany.
Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, Munich, Germany.
German Center for Mental Health (DZPG), Partner Site Munich, Munich, Germany.

Oliver Pogarell (O)

Max Planck Fellow Group Precision Psychiatry, Max Planck Institute of Psychiatry, Munich, Germany.

Nikolaos Koutsouleris (N)

Max Planck Fellow Group Precision Psychiatry, Max Planck Institute of Psychiatry, Munich, Germany.
Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, Munich, Germany.
German Center for Mental Health (DZPG), Partner Site Munich, Munich, Germany.
Munich Center for Neurosciences, LMU Munich, Munich, Germany.
Institute of Psychiatry, Psychology and Neuroscience, King's College, London, UK.

Classifications MeSH